These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28122892)

  • 21. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
    Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
    Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
    Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
    Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
    Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
    J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.
    Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
    Ann Hematol; 2014 Oct; 93(10):1725-33. PubMed ID: 24844780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Petrizzi VB; Ricci F; Crugnola M; Spriano M; Spedini P; Ilariucci F; Uziel L; Attolico I; Vismara E; De Blasio A; Zaccaria A; Morra E
    Blood; 2011 Oct; 118(15):4079-85. PubMed ID: 21772050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
    Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
    Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
    Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
    Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Keating MJ; Flinn I; Jain V; Binet JL; Hillmen P; Byrd J; Albitar M; Brettman L; Santabarbara P; Wacker B; Rai KR
    Blood; 2002 May; 99(10):3554-61. PubMed ID: 11986207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
    Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
    Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
    Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
    Lin TS; Donohue KA; Byrd JC; Lucas MS; Hoke EE; Bengtson EM; Rai KR; Atkins JN; Link BK; Larson RA
    J Clin Oncol; 2010 Oct; 28(29):4500-6. PubMed ID: 20697069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Gritti G; Reda G; Maura F; Piciocchi A; Baldini L; Molica S; Neri A; Cortelezzi A
    Leuk Lymphoma; 2012 Mar; 53(3):424-9. PubMed ID: 21919823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.